What the company does
SillaJen is a South Korean biotech company, listed on KOSDAQ, that develops experimental cancer treatments, including engineered viruses designed to infect and destroy tumour cells while stimulating the body's own immune system, and small-molecule drugs that disrupt cancer-cell division.
It also has a pharmaceutical division that develops and supplies generic and improved versions of injectable prescription medicines not previously available in Korea. The company runs two distinct business lines: an oncology drug-development programme and a commercial pharmaceutical operation.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$6.7M
▲ +134.9% YoY
Operating profit · FY2025
−US$18.5M
Loss narrowed
Net income · FY2025
−US$17.5M
Loss narrowed
Revenue
- FY2023US$2.9M
- FY2024US$2.8M
- FY2025US$6.7M
Operating profit
- FY2023−US$15.5M
- FY2024−US$19.4M
- FY2025−US$18.5M
Net income
- FY2023−US$14.8M
- FY2024−US$19.2M
- FY2025−US$17.5M
Key ratios (FY2025)
ROE
-22.0%
Debt/Eq
6.1%
Op. margin
-277.4%
Net margin
-262.2%
Rev. YoY
▲ +134.9%
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?